Ueoka H, Ohnoshi T, Hiraki S, Kawahara S, Numata T, Nishii K, Yonei T, Yamashita H, Moritaka T, Kiura K
Dept. of Medicine, Okayama University Medical School, Japan.
Gan To Kagaku Ryoho. 1989 Jun;16(6):2251-5.
A pilot phase II study of a hybrid chemotherapy for SCLC has been conducted between October 1986 and March 1988. Dose and schedule of the regimen were as follows: CTX, 700 mg/m2, on day 1; ADM 30 mg/m2, on day 1; VCR, 1.4 mg/m2, on day 1 (CAV); and CDDP, 60 mg/m2, on day 8; VP-16, 100 mg/m2, on days 8 and 9 (PVP). Courses were repeated q. 4 weeks up to 6 cycles. Patients with LD received chest irradiation at a dose of 50 Gy when maximal response was achieved. Thirty-six patients were fully evaluated for tumor response and toxicity. All 18 patients with LD responded to the regimen including 11 CRs (61%); there were 7 CRs (39%) and 9 PRs (50%) in patients with ED. Fourteen of the 18 patients with LD have survived for 7 to 22 months, against 12.8 months in ED patients. The major toxicity was myelosuppression, but it was well tolerated. These results indicate that hybrid chemotherapy is highly effective for SCLC, and warrants further clinical trials.
1986年10月至1988年3月期间进行了一项小细胞肺癌混合化疗的II期试点研究。该方案的剂量和疗程如下：环磷酰胺（CTX），700mg/m²，第1天使用；多柔比星（ADM），30mg/m²，第1天使用；长春新碱（VCR），1.4mg/m²，第1天使用（CAV方案）；顺铂（CDDP），60mg/m²，第8天使用；依托泊苷（VP-16），100mg/m²，第8天和第9天使用（PVP方案）。疗程每4周重复一次，最多进行6个周期。局限性疾病（LD）患者在达到最大缓解时接受50Gy的胸部放疗。对36例患者的肿瘤反应和毒性进行了全面评估。所有18例LD患者对该方案均有反应，其中11例完全缓解（CR，61%）；广泛期疾病（ED）患者中有7例CR（39%）和9例部分缓解（PR，50%）。18例LD患者中有14例存活了7至22个月，而ED患者的存活时间为12.8个月。主要毒性为骨髓抑制，但耐受性良好。这些结果表明，混合化疗对小细胞肺癌高度有效，值得进一步进行临床试验。
